comparemela.com

Latest Breaking News On - Michael leuchten - Page 6 : comparemela.com

SARTORIUS STEDIM BIOTECH : UBS reiterates its Buy rating

In a research note, UBS analyst Michael Leuchten has maintained his recommendation on the stock with a Buy rating. The target price is decreased from EUR 424 to EUR 390. | June 20, 2023

SARTORIUS VORZUEGE : Gets a Buy rating from UBS

Michael Leuchten from UBS retains his positive opinion on the stock with a Buy rating. The target price is revised downwards from EUR 500 to EUR 470. | June 19, 2023

NOVO NORDISK : Receives a Sell rating from UBS

In his latest research note, analyst Michael Leuchten confirms his negative recommendation. The broker UBS is keeping its Sell rating. The target price remains set at DKK 720. | June 19, 2023

Profit warning sends Sartorius to 12-month low

Surprisingly sharply lowered annual targets sent Sartorius shares to a 12-month low on Monday. After the shares of fashion retailer Zalando, they are also now the second-weakest performer so far this. | June 19, 2023

SARTORIUS VORZUEGE : UBS reiterates its Buy rating

In a research note published by Michael Leuchten, UBS advises its customers to buy the stock. The target price remains unchanged at EUR 500. | June 16, 2023

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.